This analysis examines the historical and forecast performance for Altana in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to order your copy:
-Benchmark Altanas performance against key rivals in the ethical pharmaceutical sector -See how Altanas sales growth will slump following the 2009 patent expiry of Pantazol, which dominated the companys 2005 sales -Analyze the value of Altana Pharmas ethical offerings, present and future, in view of Nycomeds recent $5.7bn acquisition of the business unit
